Isto Technologies' parent firm Isto Holdings has acquired Arteriocyte Medical Systems for an undisclosed sum.
The companies plan to integrate themselves under the name Isto Biologics, to provide evidence-based solutions for expanding its spine, orthopedics, and functional-medicine product portfolios.
With headquarters in St. Louis, Isto Biologics will maintain operations in Massachusetts.
The company's product portfolio will include Arteriocyte's Magellan autologous platelet separator and Isto's bone-growth and cell-therapy products.
The products include InQu bone graft extender and substitute, Influx natural bone-graft material and CellPoint concentrated bone marrow aspirate system.
Isto Technologies current CEO George Dunbar will serve as CEO for Isto Biologics.
Dunbar said: "We are grateful for the support of Thompson Street Capital Partners and excited to lead Isto Biologics into the future.
"The integration of Isto and Arteriocyte presents an opportunity to leverage our combined expertise to establish a strong position in an ever-changing market and better serve our physician partners, as they work to grow their practice and meet the demands of value-based healthcare."
Thompson Street Capital Partners provided capital for the transaction.
Thompson Street Capital Partners director Anthony Chambers said: "We're excited to bring together two great organizations under the Isto umbrella and build upon their leading biologics platforms.
“Both Isto and Arteriocyte have achieved remarkable success by developing innovative, clinically-proven product offerings that help improve patient outcomes.”
Image: Isto Holdings acquires Arteriocyte Medical Systems. Photo: courtesy of stockimages / FreeDigitalPhotos.net.